Member Info for Laura2022

Yes Ant

Been difficult to buy for about 5 or 6 days now ( as in difficult to get quotes for 100k to 200k or goes to negotiate trade)

About 200,000 shares seems to be the limit

Ant

Would be great if you reach out directly to Peter S

In last 3mths I have had 2 queries answered promptly and Judging by his manner and enthusiasm I am sure he would be glad to talk to you ?

Can I also echo Trench123 and King h

Thankyou Ant

Welcome back newgrange

As king H says be good if traders become investors

For £1.5mln cap one gets £900k+ revenues to he hit for 2024) and a pipeline grown from £1.mlnnto £1.5mln

Recent interims saw record H1 revenues, reduced losses, growing pipeline and a new CEO drive

Gluck

Peter promosed more events as this is increasingly important for new business

The Company's pipeline of potential new business now stands at over £1.5m (not risk weighted and excluding Biostatistics), counting only opportunities where a specific project has been discussed with a client. The Company is working hard to both convert opportunities that have progressed to proposal stage and also to refill the funnel with earlier stage opportunities. A significant number of new client contracts are now originating from both scientific conferences (such as EORTC-NCI-AACR & AACR Annual Meeting) as well as more business focused meetings

New NEDs was one of the final conditions of the $500mln sale of the Accredited business

Sorry for off discussion but with the success of oncology /SAR it's well worth looking at a drug development company that uses A.I to help clients like SAR get rgrough their trials and FDA regulations which now insist that A.I and computer modelling has been done prior to trials and submission

PYC (Physiomics)

Not enough coffee!!

2 NEDs but what CEO says (3rd para) is interesting,clearly they expect expect be moving forward from this difficult time

Particularly the 3rd one

Jeff Hayman, Chairman of R&Q, said: "Stephen and Lawrence both bring relevant additional experience to the Board, in particular with regards to our priorities of reducing debt and improving the efficiency and expense base of the go-forward business. As we continue to work towards completing the sale of Accredited, these appointments also support our ongoing discussions with lenders to achieve their necessary approvals."

 

 

DoseMeRx is a game-changing solution that enables customers to accelerate their precision dosing strategies with superior analytics and reporting. The guideposts of DoseMe’s ongoing investment are to improve overall clinical expertise and valuable clinical decision support to assist customers in offering the highest quality patient care.

This surge in clientele was boosted by strategic partnerships worldwide, underscoring DoseMe’s commitment to global expansion and continuous innovation to deliver advanced precision dosing.

Excellent news Trench

Another great day of rises

The added bonus is that AIM company is using their A.I technology to help Sareum lead assets . There is avery good chance SAR trials will be positive as the success rate of PYC tech is very high and work with Merck, Sar etc

Larger buys all shown as sells 2.94p+

Total bargain

Net assets after sale = 80 cent (60p)15 Mar 2024 18:55

Adjusted for closing of the Sale and subsequent de-leveraging of R&Q assuming Available Net Cash Proceeds of $170 million (at the lower end of the expected range), R&Q's current estimated pro-forma financial position as at 30 June 2023 would be as follows:

Assets

$2.0 billion

Debt

$203 million

Shareholders' Equity

$356 million

Debt to Capital Ratio

36%

Group Solvency Ratio

>200%

Net Asset Value Per Common Share

80 cents

'Net cash proceeds available for utilisation immediately on closing are expected to be between approximately $170 million and $210 million ("Available Net Cash Proceeds")

Nice £10k

From purchases the day of the placing

I have taken half profits

All been approved by EU

See an article posted her about 3 weeks ago